NDA 217389 · Msd
Ohtuvayre
Ensifentrine · Inhalation · Phosphodiesterase 3 Inhibitor; Phosphodiesterase 4 Inhibitor
NovelCDER novel approval, Jun 26, 2024: To treat chronic obstructive pulmonary disease
Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
5 Phase 3, 2 recruiting
FAERS reports
1,830
635 serious, 73 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 13, 2026.
OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. OHTUVAYRE is a phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. ( 1 )
Mechanism: Ensifentrine is a small molecule that is an inhibitor of the PDE3 and PDE4 enzymes. PDE3 primarily hydrolyzes the second-messenger molecule cyclic adenosine monophosphate (cAMP) but is also capable of hydrolyzing cyclic guanosine monophosphate (cGMP). PDE4 hydrolyzes cAMP only. Inhibition of PDE3 and PDE4 results in accumulation of intracellular levels of cAMP and/or cGMP, resulting in various downstream signaling effects.
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- OHTUVAYRE · ENSIFENTRINE 3MG/2.5ML · SUSPENSION, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ensifentrine" as an intervention, any sponsor and status, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07874815 · 2,136 participants (planned) · Start Nov 2, 2026 · Primary completion Apr 29, 2029
Drug: Ensifentrine; Standard of Care (SOC) · For: Pulmonary Disease, Chronic Obstructive
Sites: Hialeah Gardens, Florida; Loxahatchee Groves, Florida; Valparaiso, Indiana · 7 sites in all
- A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDPivotal-lookingCompleted
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT04542057 · 790 participants · Start Sep 22, 2020 · Primary completion May 3, 2022
Drug: Ensifentrine; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Alabaster, Alabama; Andalusia, Alabama; Jasper, Alabama · 130 sites in all
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDPivotal-lookingCompleted
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT04535986 · 763 participants · Start Sep 29, 2020 · Primary completion Sep 12, 2022
Drug: Ensifentrine; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Peoria, Arizona; Tempe, Arizona; Huntington Beach, California · 122 sites in all
- A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Nuance Pharma (shanghai) Co., LtdIndustry
NCT05743075 · 526 participants · Start Mar 10, 2023 · Primary completion Dec 6, 2024
Drug: Ensifentrine; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Guangzhou, China
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)Pivotal-lookingCompleted
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT07016412 · 497 participants · Start Jul 31, 2025 · Primary completion Aug 17, 2026
Drug: Ensifentrine 3 mg; Glycopyrrolate 21.25 mcg and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 57 sites in all
- Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDPivotal-lookingCompleted
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT03937479 · 416 participants · Start May 1, 2019 · Primary completion Nov 15, 2019
Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium; Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium and 3 more · For: COPD
Sites: Anniston, Alabama; Fullerton, California; Los Angeles, California · 50 sites in all
- Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) PatientsPivotal-lookingCompleted
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT03443414 · 405 participants · Start Jun 1, 2017 · Primary completion Jan 23, 2018
Drug: RPL554 suspension; Placebo · For: COPD
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Sofia, Bulgaria · 49 sites in all
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisPivotal-lookingRecruiting
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
NCT06559150 · 284 participants (planned) · Start Sep 11, 2024 · Primary completion Sep 24, 2027
Drug: Nebulized Ensifentrine Suspension; 3 mg; Nebulized Placebo Solution · For: Non-cystic Fibrosis Bronchiectasis
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 51 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea376
- drug ineffective132
- chronic obstructive pulmonary disease129
- diarrhoea106
- cough99
- back pain98
- pneumonia94
- product dose omission issue91
- no adverse event83
- death82
- headache75
- chest discomfort63
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 27 |
| 2025 | 783 |
| 2026 | 1,008 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ohtuvayre (Ensifentrine)
2024 spending
$113K
Beneficiaries
25
40 claims
Per beneficiary
$4,538
$18.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $113,443 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).
Anzueto A, Barjaktarevic IZ, Siler TM, et al. · Am J Respir Crit Care Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies.
Dransfield M, Marchetti N, Kalhan R, et al. · Chron Respir Dis 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD.
Sciurba FC, Christenson SA, Rheault T, et al. · Chest 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials.
Hammadeh BM, Younis OM, Alsufi MI, et al. · Ther Adv Respir Dis 2025 · Systematic Review, Meta-Analysis
- Treating chronic obstructive pulmonary disease with ensifentrine: a systematic review.
Almuntashiri S, Alfarhan M, Chase A, et al. · Front Med (Lausanne) 2025 · Systematic Review
- Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial.
Zhou Y, Chen C, Wang Z, et al. · Chest 2026 · Randomized Controlled Trial, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.